LumiraDx Limited Share Price

Equities

LMDXF

KYG5709L1095

Advanced Medical Equipment & Technology

Market Closed - OTC Markets 01:26:20 27/04/2024 am IST 5-day change 1st Jan Change
0.017 USD +10.68% Intraday chart for LumiraDx Limited -15.00% -72.97%
Sales 2021 421.43 35.14K Sales 2022 254.48 21.22K Capitalization 286M 23.84B
Net income 2021 -101M -8.42B Net income 2022 -448M -37.35B EV / Sales 2021 58,17,897 x
Net Debt 2021 200M 16.7B Net Debt 2022 347M 28.95B EV / Sales 2022 24,87,758 x
P/E ratio 2021
-14.4 x
P/E ratio 2022
-0.57 x
Employees 1,210
Yield 2021 *
-
Yield 2022
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+10.68%
1 week-15.00%
Current month+123.68%
1 month+97.67%
3 months+38.21%
6 months-86.82%
Current year-72.97%
More quotes
1 week
0.01
Extreme 0.0131
0.02
1 month
0.01
Extreme 0.007
0.03
Current year
0.01
Extreme 0.007
0.06
1 year
0.01
Extreme 0.007
0.63
3 years
0.01
Extreme 0.007
11.09
5 years
0.00
Extreme 0
11.09
10 years
0.00
Extreme 0
11.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 01/14/01
Founder 67 01/14/01
Director of Finance/CFO 49 01/16/01
Members of the board TitleAgeSince
Founder 67 01/14/01
Chief Executive Officer 70 01/14/01
Director/Board Member 69 01/16/01
More insiders
Date Price Change Volume
26/24/26 0.017 +10.68% 708,466
25/24/25 0.0154 -9.65% 369,780
24/24/24 0.017 +13.33% 718,636
23/24/23 0.015 -7.69% 412,868
22/24/22 0.0162 -18.75% 533,507

Delayed Quote OTC Markets, April 27, 2024 at 01:26 am IST

More quotes
LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. The Company offers a menu of lab comparable tests on a single portable platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. It also supports laboratory testing in an accessible high-throughput format to leverage molecular laboratory operations. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and others.
More about the company